Depression Research
Major depressive disorder, often referred to as major depression, is a heterogenous condition with complex and diverse neurobiological etiologies. Depression is characterized by a triad of symptoms: low or depressed mood, anhedonia and low energy or fatigue. Approximately 15% of the population in developed countries has been affected by depression in their lifetime and the chance of developing depression is twice as high in women. 40-50% of depressive causes are inheritable (genes as yet unidentified) and the remaining 50-60% of causes are caused by environmental stressors.
Depression Research Products Targets
- FGFR (5)
- Voltage-gated Calcium Channel (CaV) (38)
- Others (13)
- Glucocorticoid Receptor (9)
- Nucleoside Transporter (5)
- Glycine Transporter (6)
- GABA (10)
- Cannabinoid Transporter (10)
- Acetylcholine Transporter (1)
- D4 Receptor (12)
- 5-HT7 Receptor (11)
- 5-HT6 Receptor (14)
- 5-ht5 Receptor (2)
- 5-HT4 Receptor (17)
- NK2 Receptor (7)
- NK1 Receptor (15)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- AMPA Receptor (45)
- D3 Receptor (12)
- NK3 Receptor (5)
- Vesicular Monoamine Transporter (4)
- NMDA Receptor (87)
- Kainate Receptor (22)
- D2 Receptor (14)
- D1 and D5 Receptor (16)
- Trk Receptor (13)
- Trace Amine 1 Receptor (2)
- Glutamate Transporter (18)
- Dopamine Transporter (20)
- CRF2 Receptor (3)
- CRF1 Receptor (5)
- Adrenergic Transporter (23)
- 5-HT Transporter (30)
- Vasopressin Receptor (6)
- Monoamine Oxidase (10)
- Adrenergic α2 Receptor (33)
- Adrenergic α1 Receptor (22)
- Adrenergic β3 Receptor (12)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
Products for Depression Research - Page 34
- Cat.No. Product Name Information/Activity
-
BCC2512
Zonisamide
Zonisamide is a 1,2 benzisoxazole derivative and the first agent of this chemical class to be developed as an antiepileptic drug.
-
BCC6566
cis-ACPD
477331-06-9
-
BCC2894
H-D-Asp-OH
(-)-Aspartic acid is an endogenous NMDA receptor agonist.
-
BCC2881
H-Asp-OH
L-Aspartic acid is is an amino acid, shown to be a suitable prodrug for colon-specific drug deliverly.
-
BCC6571
L-Cysteinesulfinic acid
L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC50s of 3.92±0.03, 4.6±0.2, 3.9±0.2, 2.7±0.2, 4.0±0.2, and 3.94±0.08 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively.
-
BCC6013
GLYX 13
Rapastinel (GLYX-13) is an N-methyl-D-aspartate receptor (NMDAR) modulator that has characteristics of a glycine site partial agonist.
-
BCC6588
(R)-(+)-HA-966
(R)-(+)-HA-966 ((+)-HA-966) is a partial agonist/antagonist of glycine site of the N-methyl-D-aspartate (NMDA) receptor complex. (R)-(+)-HA-966 selectively blocks the activation of the mesolimbic dopamine system by amphetamine. (R)-(+)-HA-966 can cross the blood-brain barrier and has the potential for neuropathic and acute pain.
-
BCC6570
Homoquinolinic acid
490-75-5
-
BCC6591
Ibotenic acid
Ibotenic acid has agonist activity at both the N-methyl-D-aspartate (NMDA) and trans-ACPD or metabolotropic quisqualate (Qm) receptor sites.
-
BCC5896
MNI-caged-D-aspartate
845555-94-4


